The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study

References

• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165–74
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1–50
   PubMed Web of Science ®Google Scholar
• Amowitz LL, Sobel BE. Cardiovascular consequences of polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:439–58
   PubMed Web of Science ®Google Scholar
• Hansen BC. The metabolic syndrome X. Ann NY Acad Sci 1999;892:1–24
   PubMedGoogle Scholar
• Gangale MF, Miele L, Lanzone A, et al. Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011;75:520–7
   Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012;5:CD003053
   PubMed Web of Science ®Google Scholar
• Du Q, Wang YJ, Yang S, et al. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012;28:723–30
   PubMed Web of Science ®Google Scholar
• Sinawat S, Buppasiri P, Lumbiganon P, Pattanittum P. Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS. Cochrane Database Syst Rev 2012;10:CD006226
   PubMedGoogle Scholar
• Larner J. Multiple pathways in insulin signalling: fitting the covalent and allosteric puzzle pieces together. Endocr J 1994;2:167–71
   Google Scholar
• Ortmeyer HK, Bodkin NL, Lilley K, et al. Chiroinositol deficiency and insulin resistance. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 1993;132:640–5
   PubMed Web of Science ®Google Scholar
• Suzuki S, Kawasaki H, Satoh Y. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type II diabetes. Diabetes Care 1994;17:1465–8
   PubMed Web of Science ®Google Scholar
• Kennington AS, Hill CR, Craig J. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1990;323:373–8
   PubMed Web of Science ®Google Scholar
• Asplin I, Galasko G, Larner J. Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993;90:5924–8
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300–5
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8:127–36
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314–20
   PubMed Web of Science ®Google Scholar
• Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol 2011;27:256–62
   PubMed Web of Science ®Google Scholar
• Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390–7
   PubMed Web of Science ®Google Scholar
• Sacchinelli A, Venturella R, Lico D, et al. The efficacy of inositol and N-acetyl cysteine administration (OvaricHP) in improving the ovarian function in infertile women with PCOS with or without insulin resistance. Obstet Gynecol Int 2014;2014:141020
   PubMedGoogle Scholar
• Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014;30:438–43
   PubMed Web of Science ®Google Scholar
• Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003;14:365–70
   PubMed Web of Science ®Google Scholar
• Kalme T, Koistinen H, Loukovaara M, et al. Comparative studies on the regulation of insulin-like growth factorbindingprotein-1 (IGFBP-1) and sex hormone-binding gobulin (SHBG) production by insulin and insulin-like growth factors in humanhepatoma cells. Steroid Biochem Mol Biol 2003;86:197–200
   Google Scholar
• Castracane VD, Kauffman RP. Assessing insulin sensitivity. Contemporary OB/GYN 2003;48: 30–5
   Google Scholar
• Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome – a positionstatement of the Androgen Excess Society. J Clin Endocrinol Metab 2007;92:4546–56
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647–54
   PubMed Web of Science ®Google Scholar
• Kołodziejczyk B, Dulęba AJ, Spaczyński RZ, Pawelczyk L. Metformintherapy decreases hyperandrogenism and hyperinsulinemia in womenwith polycystic ovary syndrome. Fertil Steril 2000;73:1149–54
   PubMed Web of Science ®Google Scholar
• Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8:417–23
   PubMedGoogle Scholar
• Baillargeon JP, Iuorno MJ, Jakubowicz DJ, et al. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:242–9
   PubMed Web of Science ®Google Scholar
• Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7:151–9
   PubMedGoogle Scholar
• Baillargeon JP, Nestler JE, Ostlund RE, et al. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008;23:1439–46
   PubMed Web of Science ®Google Scholar
• La Marca A, Orvieto R, Giulini S, et al. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82:970–2
   PubMed Web of Science ®Google Scholar
• Tal R, Seifer DB, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211:59.e1–8
   Google Scholar
• Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review andmeta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332–40
   PubMed Web of Science ®Google Scholar
• Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphologyand polycystic ovary syndrome: a prospective cohort study. Hum Reprod 2013;28:1077–83
   PubMed Web of Science ®Google Scholar
• La Marca A, Broekmans FJ, Volpe A, et al.; ESHRE SpecialInterest Group for Reproductive Endocrinology–AMH Round Table. Anti-Mullerianhormone (AMH): what do we still need to know? Hum Reprod 2009;24:2264–75
   PubMed Web of Science ®Google Scholar
• La Marca A, Volpe A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf) 2006;64:603–10
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M, et al. Granulosa cell production of anti-Müllerian hormone is increased in polycysticovaries. J Clin Endocrinol Metab 2007;92:240–5
   PubMed Web of Science ®Google Scholar
• Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task orce report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2013;20:334–52
   Google Scholar
• Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycysticovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab 2014;99:1870–8
   PubMed Web of Science ®Google Scholar
• Johnson NP, Bontekoe S, Stewart AW. Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. Aust N Z JObstet Gynaecol 2011;51:252–6
   Google Scholar
• Mehrabian F, Afghahi M. Can sex-hormone binding globulin considered as a predictor of response to pharmacological treatment in women with polycystic ovary syndrome? Int J Prev Med 2013;4:1169–74
   Google Scholar
• Sun B, Wang F, Sun J, et al. Basal serum testosterone levels correlate with ovarian response but do not predict pregnancy outcome in non-PCOS women undergoing IVF. J Assist Reprod Genet 2014;31:829–35
   Google Scholar